Atlas Venture Associates Opportunity I, LLC, 10% Owner at Kymera Therapeutics, Inc. (KYMR), sold 705,669 shares at $42.19 ($29.8M) on 2024-03-13, disclosed to the SEC on 2024-03-13.
Scheduled sale ($29.8M) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.77 | 7,837 | $335K | 1.1% |
| 2 | $42.77 | 7,837 | $335K | 1.1% |
| 3 | $42.77 | 37,180 | $1.6M | 5.3% |
| 4 | $42.77 | 37,180 | $1.6M | 5.3% |
| 5 | $43.42 | 5,122 | $222K | 0.7% |
| 6 | $43.42 | 5,122 |
| $222K |
| 0.7% |
| 7 | $43.42 | 1,045 | $45K | 0.2% |
| 8 | $41.94 | 26,452 | $1.1M | 3.7% |
| 9 | $41.94 | 26,452 | $1.1M | 3.7% |
| 10 | $41.94 | 126,066 | $5.3M | 17.8% |
| 11 | $41.94 | 126,066 | $5.3M | 17.8% |
| 12 | $42.52 | 1,819 | $77K | 0.3% |
| 13 | $42.52 | 1,819 | $77K | 0.3% |
| 14 | $42.52 | 8,581 | $365K | 1.2% |
| 15 | $42.52 | 8,581 | $365K | 1.2% |
| 16 | $42.19 | 108,404 | $4.6M | 15.4% |
| 17 | $42.19 | 22,779 | $961K | 3.2% |
| 18 | $42.19 | 22,779 | $961K | 3.2% |
| 19 | $42.19 | 108,404 | $4.6M | 15.4% |
| 20 | $42.84 | 1,386 | $59K | 0.2% |
| 21 | $42.84 | 1,386 | $59K | 0.2% |
| 22 | $42.84 | 6,686 | $286K | 1.0% |
| 23 | $42.84 | 6,686 | $286K | 1.0% |
| Total | $42.20 avg | 705,669 | $29.8M | 100% |
| Filing → |
| IKNA | BUY | 2021-12-14 | $2.0M | — | Filing → |
| IKNA | SELL | 2021-12-14 | $688K | — | Filing → |
| GBIO | SELL | 2021-06-23 | $9.3M | — | Filing → |